Oncology Liquid biopsy Screening and monitoring Research and Innovations Molecular Pathology

Urine Bladder Cancer Test Could Triage Cystoscopy

Real-world UK study suggests molecular testing could help prioritize patients with hematuria for urgent bladder investigation

09/11/2026 News 2 min read

Share

Clinical Scorecard: Urine Bladder Cancer Test Could Triage Cystoscopy

At a Glance

Category	Detail
Condition	Bladder Cancer
Key Mechanisms	Urine-based DNA test using next-generation sequencing to detect mutations associated with bladder cancer.
Target Population	Patients with hematuria referred for urgent cystoscopy.
Care Setting	Urology departments in the UK National Health Service.

Key Highlights

GALEAS Bladder assay detected 71 of 77 bladder cancers.
Negative predictive value exceeded 99 percent.
Modeling suggested a reduction of 730 urgent cystoscopies per 1000 patients.
Assay detected all muscle-invasive cancers and most high-grade cancers.
Study supports molecular testing as a triage tool, not a replacement for cystoscopy.

Guideline-Based Recommendations

Diagnosis

Use GALEAS Bladder assay to identify patients needing urgent cystoscopy.

Management

Negative results can support deferred cystoscopy with appropriate surveillance.

Monitoring & Follow-up

Patients with positive results should be prioritized for prompt cystoscopy.

Risks

Incomplete follow-up for patients with positive molecular results but negative standard investigations.

Patient & Prescribing Data

Patients with hematuria referred for cystoscopy.

Molecular testing can guide urgency of cystoscopy.

Clinical Best Practices

Implement molecular testing as a triage tool in hematuria investigations.
Ensure appropriate follow-up for patients with positive molecular results.

Related Resources & Content

European Urology Oncology